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ABSTRACT 
 
Effect of CD20 channel activity on the efficacy of 
rituximab and obinutuzumab 
 
Woon Heo 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Joo Young Kim) 
 
CD20 is the first member of four transmembrane spanning family (MS4A) 
protein, and is a target protein for the rituximab, a monoclonal antibody for the 
treatment of non-Hodgkin lymphoma and chronic arthritis. Although several previous 
studies have reported that CD20 function as a Ca2+ channels, especially activated by 
store depletion, the molecular mechanism to identify the Ca2+ channel features of 
CD20 are still elusive. Meanwhile, rituximab in known to cause Ca2+ signaling 
through CD20 binding, but the Ca2+ signaling effects of the two improved monoclonal 
antibodies, obinutuzumab, and ofatumumab were not reported yet.  
Therefore, purpose of this study is demonstration 1) the characterization of 
CD20 as a SOC Ca2+ channel regulated by STIM1 in a Orai1 dependent manner and 
2) how the Ca2+ signal through SOC mechanism will influence the characteristic or 
efficacy of each antibody.  
Protein interaction between CD20 and STIM1 was increased in store 
depleted condition, but their interaction was dependent on the presence of orai1. Both 
rituximab and obinutuzumab showed Ca2+ influx from the outside of cells, but CD20 
protein interactions with STIM1 had different effects depending on the type of 
antibody. In the case of rituximab, the effect of CD20 binding to STIM1 was 
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negligible in the Ca2+ influx, whereas the amount of Ca2+ influx from the outside were 
significantly increased in STIM1 co-expression by obinutuzumab. And the ability of 
obinutuzumab to bind CD20 decreased by siRNA targeting orai1. Subsequently, 
homotypic adhesion by obinutuzumab didn’t occur when the external Ca2+ free 
solution. However, the external Ca2+ concentration didn’t alter the dose dependent 
cell death via the direct obinutuzumab binding. Interestingly, external Mg2+ 
concentration altered the rate of the cell death induced by direct obinutuzumab 
binding.  
Therefore, I suggest that the CD20 is a component of ion channel regulated 
by STIM1 and Orai1. Moreover, the ion channel activity of CD20 could contribute 
to the B cell depletion efficacy of obinutuzumab via permeating Mg2+.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key words: CD20, STIM1, SOCE, rituximab, obinutuzumab, ofatumumab, 
Ca2+, Mg2+ 
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I. INTRODUCTION 
 
CD20 is a 4 transmembrane protein, one of the MS4A family (MS4A), 
expressed exclusively in B cells.1 CD20 is used as the target of antibody for depleting 
the mature B cell and lymphoma. Those antibodies do not cause total collapse of the 
adaptive immune response, because pro-B cell and plasma cell do not express CD20 
among B cells.2  
CD20 is known as a raft localized protein which has a raft localizing region 
in its cytoplasmic C-terminal tail near the fourth transmembrane domain3. Especially, 
rituximab binding to CD20 causes CD20 aggregation into raft region, which is one 
of the typical characteristics of type1 categorized antibody.4 Through aggregated 
CD20, rituximab-like type 1 antibodies enhance the interaction with complement, 
which in turn causes cell death. In contrast, type 2 antibody, like obinutuzumab, 
works mainly through the antibody dependent cell mediated cytotoxicity.5,6 It has 
been focused on that the Fc region of the antibody determines the action mechanism 
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of these types of antibodies. But recent reports revealed that antigen recognition 
modes are also important for the function of antibodies.7,8 In fact, non-glycosylation 
form of obinutuzumab, GA101 also showed the similar ADCC activity as 
glycosylated form of obinutuzumab, in spite of their distinct affinity to the Fc gamma 
receptor.5,9 In addition, it is known that the epitope region of rituximab and 
obinutuzumab are the same extracellular big loop of CD20 according to the epitope 
finding analysis using amino acid scan. However, the configurations of CD20 bind to 
antibodies including the binding angles is different according to the structural 
analysis.8 Therefore, it seems that the configuration of target protein CD20 and the 
binding mode of antibodies also contribute to their potency of B cell depletion.  
However, the basic molecular mechanism and interactions between CD20 
and its antibody was not well understood as much as the clinical efficacy studies of 
CD20 antibodies. Especially, although previous studies have shown that CD20 
transfected cells show SOCE (store operated Ca2+ entry) activity greater than mock, 
indicating that CD20 is a SOC(store operated Ca2+ channel) 10,11, there is no molecular 
mechanism study of the channel activity of CD20 or its effect on antibody function. 
Ca2+ is not only important to cell growth and death, but also involved in a 
variety of signaling processes maintain the homeostasis of cells. Intracellular Ca2+ is 
maintained in a few nM level. This Ca2+ acts as a signaling material when the 
concentration is increased by the influx of external Ca2+ or efflux from internal Ca2+ 
store. High concentration Ca2+ in the cytoplasm that acts as a signal is returned to the 
low level again by PMCA (plasma membrane Ca2+ ATPase), which exports Ca2+ to 
the outside of the cell, or SERCA (sarcoendoplasmic reticulum Ca2+ ATPase), which 
brings Ca2+ back into the intracellular Ca2+ reservoir. However, in this process, the 
Ca2+ inside the reservoir is gradually consumed, and a mechanism for receiving Ca2+ 
from the outside of the cell is needed. The Ca2+ channel which present in the cell 
membrane activated by the depletion signal of the intracellular Ca2+ reservoir is 
referred to as a ‘store operated Ca2+ channel (SOC)’.12 
STIM1 was first identified as a protein that present increased expression in 
B-cell lymphocytes and cancer.13,14 In 2006, it was found as the only regulatory switch 
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of SOCE.15,16 STIM1 is a protein with one transmembrane region mainly localized in 
the ER membrane. The EF hand of STIM1 at the N-terminus detects the Ca2+ 
concentration in the ER and STIM1 controls the opening and closing of the SOC 
channels such as orai1 in the cell membrane through the C-terminal SOAR (STIM1  
orai activating region) region.17 Since the known all SOC channel such as Orai1, 
TRPC1, and TRPC4 bind to and being regulated by STIM1, the protein binding to 
STIM1 has become a decisive criterion for the determining as a SOC channel. As 
discussed above, CD20 is reported as a SOC channel which is activated by treating 
Tg (thapsigargin), a drug that depletes Ca2+ in the Ca2+ reservoir. However, there is 
no report whether CD20 binds to STIM1. Furthermore, the effect of the other CD20 
antibodies on Ca2+ signal, except rituximab were not investigated yet. Therefore, 
understanding the molecular mechanism of Ca2+ influx through CD20 and its effects 
on the efficacy of CD20 antibodies might contribute to not only for the development 
of antibodies, but also for the prevention from their side effects.  
In this study, I investigate the typical characteristics of CD20 as a Ca2+ pore 
which is regulated by store depletion. In addition, The Ca2+ influx through CD20 
triggered by three different kinds of CD20-antibodies, rituximab, ofatumumab, and 
obinutuzumab, produced in our lab. Moreover, this Ca2+ influx induced by those 
antibodies have effect on the typical changes of B cells and the efficacy of B cell 
depleting.  
 
.  
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II. MATERIALS AND METHODS 
 
1. Cells and transfection 
Human B-lymphoma RAMOS cell line was purchased from the Korean Cell 
Line Bank. Cells were maintained in RPMI1640 media supplemented with 10% FCS 
and 1% penicillin/streptomycine at 37°C, 5% CO2. HEK 293T cell line was 
maintained in DMEM media supplemented with 10% FBS and 1% 
penicillin/streptomycine at 37°C, 5%. For expressing CD20 or STIM1 in HEK cells, 
Lipofectamin 2000 reagent was used according to the standard protocol 
recommendations. 
 
2. Reagents and solutions 
cell cultures, DMEM culture medium (Dulbecco’s modified Eagle medium, 
11995-065), RPMI 1640 (Roswell Park Memorial Institute medium, 11875-093), 
Fetal bovine serum (FBS) (26140-079), Penicillin-streptomycin (15140-122; Gibco, 
Life technologiesTM, Carlsbad, CA, USA); Trypsin-EDTA 0.05% solution (25300-
062; Gibco, Life technologiesTM, Carlsbad, CA, USA) were used. For RT-PCR 
analysis, TRIzol reagent (Invitrogen, Life technologiesTM, Carlsbad, CA, USA); 
AccuScript High Fidelity 1st Strand cDNA Synthesis Kit (200436; Agilent 
Technologies, Santa Clara, CA, USA); SolgTM 2x Taq PCR Smart mix (STD02-M10h; 
SolGent Co., Daejeon, Korea) were used. 
For immunoblotting, NaCl (S7653), Triton X-100 (T8787), Glycerol (G5516; 
Sigma Aldrich); EDTA (15694, Usb, USB Coporation, Cleveland, OH, USA); Tris 
Ultrapure (T1501, Duchefa, Haarlem, The Netherlands); Complete proteinase 
inhibitors (Roche Applied Science, Mannheim, Germany); HCl (084-05425), NaOH 
(196-05375, Wako, Osaka, Japan); BCA Protein Assay Kit (23227; PierceTM, Thermo 
Scientific, Rockford, IL, USA); 5x Tricine-SDS sample buffer (KTR020-5), pre-
made 4-12% gradient SDS-PAGE gels (KG5012) (KOMA Biotech, Seoul, Korea) 
were used. 
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For Ca2+ imaging experiments, NaCl (S7653), KCl (P5405), MgCl2 (M8266), 
Glucose (G6152), HEPES (H3375), CaCl2 (C1016), EGTA (E3889), and Fura-2 AM 
(F1201; Invitrogen, Molecular probes, Eugene, Oregon, USA) were used. 
For immunocytochemistry, 4% Paraformaldehyde (19943), BSA (10857; 
Affymetrix, Cleveland, Ohio, USA); Horse serum (16050-122, Gibco); Gelatin 
(G1890), Na3N (S2002), Phosphate-buffered saline (PBS) (P5493, Sigma Aldrich) 
were used. 
 
3. Antibodies and fluorescent dyes 
Anti-Stim1 (610954; BD Transduction LaboratoriesTM San Jose, CA, USA), 
Alexa Fluor-rhodamine (A11004, Invitrogen, Molecular probes, Eugene, Oregon, 
USA) were used.  
 
4. Generation of Mab-producing CHO cells 
To generate cells stably expressing rituximab, obinutuzumab, or ofatumumab, 
lentiviruses was produced expressing heavy chain or light chain of the three 
antibodies, GNT3, or MAN2A (for the design of the lentiviruses, see Suppl Fig 1). 
CHO-RTX and CHO-OFA cells were generated by co-transduction of CHO-K1 cells 
(ATCC) with the same titers of HC and LC viruses followed by double selection with 
growth medium containing 10 μg/mL puromycin (Sigma) and 10 μg/mL blasticidin 
S (Sigma) for a week. CHO-K1 cell was transduced with LVX-GNT-Hygro and LVX-
MAN2A-Bleo viruses and selected with 500 μg/mL of hygromycin (AG Scientific) 
and 100 μg/mL of zeocin (Invitrogen) for a week. The resulting CHO-GE cell was 
transduced with lentiviruses expressing HC and LC of obinutuzumab and selected 
with 10 μg/mL puromycin and 10 μg/mL blasticidin S. Over-expression of myc-
rGnT3 was proved by WB analysis with anti-myc antibody and mRNA expression of 
rGnT3 and Man3 was proved via RT-PCR analysis. 
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5. Production and purification of Mab 
CHO-RTX, CHO-GE-OBI, and CHO-OFA cells grown to 80% confluency in 
RPMI containing 10% FBS and 10 μg/mL ciprofloxacin (Sigma) were washed twice 
with PBS and refreshed with EX-CELL® CD CHO Serum-Free media (Sigma) 
containing 1 mM sodium butyrate. Conditioned media containing Mab were obtained 
by further incubation for 10 days at 30°C in 5% CO2/95% air. Antibodies were 
purified via affinity chromatography using protein A-Sepharose bead (GE Healthcare 
Life Sciences). Buffer-changed and concentration was conducted by ultrafiltration 
with Amicon® Ultra-2 before filter-sterilization and storage. The proteinous 
characteristic of antibodies were analyzed by SDS-PAGE and coomassie blue 
staining and quantification of each antibody concentration was indirectly measured 
via substraction according to relative band intensity of 0.2, 0.4, 0.8, 1.6, 3.2 ug of 
BSA as standard. 
To produce the rituximab, obinutuzumab, and ofatumumab in CHO cells, DNA 
sequence of each mAb were delivered from Drugbank(rituximab), patent document 
(Sequence 3 from patent US 6897044- heavy chain, Sequence 1 from patent US 
6897044- light chain) and then each light and heavy chain DNA poly nucleotide 
sequence was synthesized from Bioneer company then inserted into pLenti6 viral 
vector. Each light and heavy chain was transfected into HEK cells to produce 
Lentivirus particle. Then both light and heavy chain expressing Lentivirus was 
infected in CHO cells then infected cells were selected with blasticidin and 
Puromycin. The selected cells were multiplied to 5 flasks of T75 then sodium butyrate 
was treated to erase any methylated DNA to increase the expression level of antibody. 
The cell media grown for 10 days was collected then secreted antibody was collected 
using protein A beads. The concentration of antibody was measured with SDS-PAGE 
and coomassie staining with BSA as a standard. Since obinutuzumab is glycol-
engineered antibody having highly Gln residue in Fc region, the glyco-CHO cells was 
produced which is rGnT3 and MAN2 over-expressing cells via the selection through 
resistant from hygromycin and zeocin after infection of LVX-GNT-Hygro and LVX-
MAN2A-Bleo viruses. Both expression was checked with myc-rGnT3 protein and 
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mRNA of each construct. 
 
6. Reverse-transcriptase PCR analysis 
Total RNA was extracted with TRIzol reagent according to the manufacturer’s 
instructions. cDNA was synthesized using AccuScript High Fidelity 1st Strand cDNA 
Synthesis Kit according to the manufacturer’s instructions. RT-PCR was performed 
in triplicate using SolgTM 2x Taq PCR Smart mix. Each RT-PCR reaction contained 
100 ng of cDNA. The thermocycling conditions of RT-PCR were an initial 
denaturation at 95 °C for 5 min followed by 31~37 cycles of 95°C for 30 sec, 58°C 
for 40 sec and 72°C for 40 sec, and a last extension at 72°C for 7 min. 
The primer sets are provided as follows (S, sense; AS, antisense) were used for 
PCR analyses for CD20, S, 5’- TCTTCACTGGTGGGCCCCAC-3’ and AS, 5’- 
CCTCTTTGCTGCCATTTCTGGAAT-3’; for Stim1, S, 5’-GGAAGACCTCAA 
TTACCATGAC-3’ and AS, 5’-GCTCCTTAGAGTAACGGTTCTG-3’; for Orai1, S, 
5’-TGTTTGCCCTCATGATCAGCAC-3’ and AS, 5’-AAACTCGGCCAGCTCATT 
GAG-3’. 
 
7. Immunoblotting 
HEK293T cells were seeded into 6-well plates at 1 x 106 cells/well and incubated 
at 37 °C in an incubator enriched with 5% CO2 atmosphere incubator overnight. Then, 
cells were lysed in lysis buffer [150 mM NaCl, 5 mM Na-EDTA, 10% glycerol, 20 
mM Tris-HCl pH 8.0, 0.5% Triton X-100, and complete proteinase inhibitors]. 
Protein concentration was quantified using a colorimetric method Bradford Protein 
Assay according to the manufacturer’s instructions. The lysates (40 μg of protein) 
were eluted with 5x Tricine-SDS sample buffer, and the eluted lysates were separated 
on pre-made 4-12% gradient SDS-PAGE gels. Primary antibodies included anti-flag, 
anti-myc, and caveolin; appropriate secondary antibodies were used. 
 
8. Single live cell [Ca2+]i imaging 
Single live cell [Ca2+]i imaging was measured by recording [Ca2+]i with Fura-2 
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AM labeling at dual excitation wavelengths of 340/380 nm ratiometrically. 5-10 x 104 
HEK293T cells were plated in 18 mm φ cover glass (Paul Marienfeld GmbH & Co. 
KG, Lauda-Königshofen, Germany). After appropriate transfection, the cells were 
added with cell-permeable 2 μM Fura-2 AM and incubated at 37 °C in an incubator 
enriched with 5% CO2 atmosphere incubator for 30 min, and trapped Fura-2 
fluorescence was measured with a spectrofluorometer (Photon Technology 
International, Birmingham, NJ, USA). Cells were perfused with a solution containing 
150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM glucose, 10 mM HEPES (pH 7.4 
adjusted with NaOH) containing either 1–2 mM CaCl2 or 5 mM EGTA (to chelate 
any Ca2+ in the solution). The osmolality of all solutions was adjusted to 310 osm 
with the major salt. The Fura-2 ratio was recorded using dual-excitation wavelengths 
at 340 and 380 nm, and emission wavelengths above 510 nm were monitored. Cells 
were treated with 5 μM TG which inhibits the sarcoendoplasmic reticulum Ca2+-
ATPase. Cells were treated with 2mM CaCl2 and then each single whole cell 
boundary was drawn and analyzed the intracellular Ca2+ concentrations [Ca2+]i) 
during the experiments. 
 
9. Immunocytochemistry 
HEK cells were transfected with pcDNA3.1-mCherry CD20 plasmid then the 
CD20 specific recognition of each purified antibody were tested with 
immunocytochemistry. HEK cells cultured in 18 mm cover slips and pcDNA3.1-
mCherry-CD20 plasmid were transfected with Lipofectamine2000 (Invitrogen, cat 
no. 11668019). After 48 hours, cells were fixed with 3.7% formaldehyde in PBS, then 
non-specific binding were blocked by 30 min incubation in blocking solution (5% 
horse serum, 1% gelatin, 5% BSA in PBS). rituximab, ofatumumab, and 
obinutuzumab were treated for 1 hour then 2nd anti-Fc specific human IgG 
conjugated with FITC was treated to bind each 1st antibodies. DAPI (5ug/ml) was 
used for nucleus staining. CD20 expressing cells were identified via the fluorescence 
of tagged mCherry (red) and the binding of each antibody was visualized by FITC 
fluorescence of 2nd antibody. Image was taken from the Zeiss 780 confocal 
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microscopy.  
In RAMOS cells, each antibody was treated at 37C for 15 min in presence of 
absence of Ca2+ in PBS then fixed with 3.7% formaldehyde for 5 min at RT then 
washed with PBS for three times. 2nd anti-Fc specific human IgG conjugated with 
FITC was treated to bind each 1st antibodies. To permeabilize the cell membrane, 
0.1 % triton in PBS was treated then goat anti-CD20 (Santa-cruz, cat no. sc-7735) 
were treated then anti-goat IgG specific 2nd antibody conjugated with Alexa568 were 
used to visualized the total CD20. Caveolin were stained with anti-caveolin1 antibody 
(enogene, cat no. E18-6386) then it was visualized with anti-rabbit IgG specific 2nd 
antibody conjugated with Alexa 350 (blue). 
 
10. Measurement of complement cell death, antibody mediated cell death, 
and direct antibody mediated cell death 
For measure various cell death assay, 5 x 104 cells/well RAMOS cells were 
plated in 12 well plate then 1uM calcein-AM was treated for 30 min in 37C for 
staining of healthy viable cells. Cells were resuspended into 500ul of media then 
indicated dose of antibody (0.1, 0.3, 1. 3, and 10ug/ml) were treated for 10 min. Next 
step is diverged into CDC, ADCC, and direct antibody binding mediated cell death 
via used materials. For measurement of complement dependent cell death assay, 
rabbit complement MA were added a quarter of the total volume and incubated in 
37C CO2 incubator for 2 hr. For antibody-dependent cell mediated cell death, same 
method with complement dependent cell death assay was used. After each 
concentration of antibodies treatment, purified PBMC (PBMC: RAMOS = 5:1) was 
incubated at 37C CO2 incubator for 4 hr. For measurement of direct antibody binding 
mediated cell death, cell treated with indicated antibodies were incubated at 37C 
incubator for 24 hr without any complement or effector cells. % of cell lysis (% of 
fluorescence loosing cells number among 10,000 counted total cell) was calculated 
by FACSVerse (BD Biosciences) and FlowJo software. 
 
11. Purification of PBMC cells 
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PBMC was purified with the total blood from health donors who was voluntarily 
participated in our experiment according to IRB procedure approved by the 
committee of Yonsei severance IRB board. All procedures were approved by IRB (#4-
2016-0600). Briefly, 4 ml of blood sample were centrifuged with 1600 x g. Cell 
removed serum were resuspended with 8 ml of PBS and loaded onto 4 ml of ficoll 
(HISTOPAQUE-1077, Sigma, 10771) then centrifuged at 400 g for 35 min at 20℃ 
to separate white blood cells from red blood cells. The white blood cell layer was 
collected into new tubes then washed three times (centrifuge 300g for 10 min) with 
RPMI media to completely remove the platelet. Purified PBMC cells was counted 
then incubate in RPMI media until use.  
 
12. Measurement of Ca2+ influx by antibodies via FACS 
Ca2+ influx through CD20 was measured using Ca2+ sensitive fluorescence dye 
Fluo-4 and FACS. To variate the expression level of CD20, HEK cells were 
transfected with 0.4 ug and 4 ug of pcDNA3.1-CD20 using Lipofectamine2000 for 
48 hours to produce high and low CD20 expressed HEK cells respectively. Celle were 
detached from the plate with the sheered flow of media to keep the integrity of surface 
expressed CD20, then cells were incubated with 2 uM Fluo-4 for 30 min. Then cells 
were resuspended with 2 mM Ca2+ Regular solution (mM: 140 NaCl, 5 KCl, 1 MgCl2, 
2 CaCl2, 10 glucose and 10 HEPES (pH 7.4 adjusted with NaOH, 310 osmolality 
with NaCl). 1X 105 cells were used for fluorescence counting and no Fluo-4 treated 
cells were used for negative control of fluorescence. Before treat antibody, basal 
status of [Ca2+]i was measured by fluorescence level of Fluo-4 loaded cell. Then the 
change of [Ca2+]i by rituximab, ofatumumab, and obinutuzumab including Human 
IgG (control) were measured after 10 min after treatment and cross linking antibody 
(goat anti-Human IgG Fc specific) was also used at the end of the measuring to 
confirm the capability of cells to produce Ca2+ influx. Same method was used to 
RAMOS cells and 5x105 cells were used and 5x104 cells were counted.  
 
13. Quantification of Raft localized CD20 through Triton solubility test 
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Aliquots of 5 × 106 RAMOS cells per sample were incubated at 37°C for 30 min 
in complete culture medium either alone or supplemented with 10 μg/mL antibody or 
10 μg/mL isotype control. After centrifugation at 500g for 10 min, 
 
14. Statistical analysis 
Data are presented as the means ± standard error of the mean. Statistical analysis 
was performed with Student's t-test or with analysis of variance (ANOVA), followed 
by Tukey's multiple comparison and one-way or two-way ANOVA tests using the 
GraphPad Prism software package (version 5.0), as appropriate. P<0.05 was 
considered statistically significant. 
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III. RESULTS 
 
1.  Ca2+ entry via CD20 in CD20 overexpressing HEK Cells 
HEK cells expressing either exogenous CD20 or STIM1 were loaded with 
fura-2 AM, the Ca2+-sensitive dye, and the fluorescence changes in each single cells 
were recorded. Intracellular Ca2+ stores were depleted by Tg(Thapsigargin). The Ca2+ 
influx activity of CD20 was compared with Orai1 using HEK cells co-expressing 
Orai1 and STIM1 as positive control. To confirm the Ca2+ influx activities of CD20 
and Orai1 enhanced by STIM1 interaction, STIM1ΔERM was used as a negative control 
which does not have the channel binding domain. TG treatment in the absence of 
extracellular Ca2+ cause the depleting the Ca2+ in ER (endoplasmic reticulum) and 
increase [Ca2+]i. After reaching the basal level of [Ca2+]i, the subsequent perfusion of 
2 mM Ca2+ solution induced a large increase of [Ca2+]i in CD20 overexpressed cells 
(Fig. 1A). Basal [Ca2+]i level of each condition were quantified from the resting level 
of ratio (Fig. 1C) and the relative Ca2+ influx activities were summarized by the 
largest ratio value after 2 mM Ca2+ perfusion (Fig. 1D). There was no big difference 
in basal [Ca2+]i level among groups. However, the relative Ca2+ influx activity was 
increased in CD20 transfected cells. Although not greater than that of the positive 
control, relative Ca2+ influx activity was further increased in the group co-expressing 
CD20 and STIM1 and this increase disappeared when co-expressed with STIM1ΔERM. 
Taken together, CD20 has the potential to interact with and regulated by STIM1 as 
SOC channel. 
 
2.  Increased protein interaction of CD20 and STIM1 in Ca2+ store 
depleted condition and identification of interaction region 
Previously, CD20 is known to as a Ca2+ channel and Ca2+ imaging data indicated 
that the Ca2+ influx is regulated by SOC mechanism. To check whether CD20 interact 
with STIM1 as a SOC channel, co-IP (immuno-precipitation) and immuno-
cytochemistry assayed for CD20 and STIM1 interaction. As a result, CD20 and STIM 
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Figure 1. CD20 is a store operated channel regulated by STIM1. (A) 
Representative trace of [Ca2+]c changes by CD20 depending on STIM1 interactions 
in HEK cells. CD20 was co-expressed with pcDNA3.1(Mock), STIM1, and 
STIM1ΔERM in HEK cells then the live imaging of Fura-2 AM loaded each single cell 
was recorded. (B) Representative trace of [Ca2+]c changes by Orai1 depending on 
STIM1 to compare the magnitude of Ca2+ influx mediated by CD20 and STIM1. (C) 
The level of basal [Ca2+]c in the each indicated condition. The begging ratio were 
used for the quantification and the fold of pcDNA3.1 transfected cells mock cells 
level were presented as a graph. (D) The relative Ca2+ influx activities. The traces of 
indicated number of cells were used for analysis. *p<0.05, **p<0.01, ***p<0.001, 
and ns, not significant. 
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were found to interact with each other, and their association was further enhanced by 
Tg induced store depletion (Fig. 2A). Moreover, STIM1D76A, the constitutively active 
mutant of STIM1 showed the strongest interaction with CD20 in unstimulated 
condition. 
Next, to determine the binding region for CD20-STIM1 interaction, C-terminal 
truncated CD20, CD20ΔCT was used for co-IP with STIM1. Since the truncated 
CD20ΔCT failed to interact with STIM1D76A, the C-terminus region of CD20 is 
supposed to be essential for their interaction (Fig. 2B-C). Their increased interaction 
in store depletion was also observed in immunostaining analysis. HEK293 cells co-
transfected CD20 and STIM1 treated with Tg (Fig. 2D). Their co-localization in 
puncta at Tg treatment indicate that the store depletion cause CD20 and STIM1 
interaction in HEK cells. 
 
3.  Ca2+ influx via CD20 regulated by STIM1 is dependent on Orai1 
To further explore the mechanism underlying the Ca2+ influx by CD20, whether 
CD20 channel activity is dependent on the existence of Orai1 was investigated. The 
small interference RNA targeting Orai (siOrai1) inhibited relative Ca2+ influx 
activities of either CD20 or STIM1 expressed cells even in samples that are expressed 
together (Fig. 3A). And at a gradual increase in Orai1 expression, the amount of CD20 
interacting with STIM1 also increased (Fig. 3B). These results indicate that CD20 
constitute the channel complex with Orai1 and Ca2+ influx via CD20 regulated by 
STIM1 is dependent on orai1. These data imply that the store operated property of 
CD20 is probably dependent on the Orai1 regulation by STIM1, rather than the direct 
regulation by STIM1. 
 
4.  Expression of CD20, STIM1 and Orai1 and their interaction in 
RAMOS cell 
Next, the channel components expression was confirmed mRNA and protein 
level. Then, to investigate to their physiological interaction, co-IP experiments was 
performed using the lysate form RAMOS cell, a human Burkitt's lymphoma cell  
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Figure 2. Enhanced protein interaction of CD20 and STIM1 in Ca2+ store 
depleted condition. (A) Store depletion enhances protein interaction of CD20 and 
STIM1. Immunoprecipitated STIM1 protein was observed to show the CD20 and 
STIM1 protein interaction in HEK cells over-expression with flag-CD20 and myc-
STIM1. 5 uM Tg and STIM1D76A (constitutive active form) were used to show the 
enhanced protein interaction between CD20 and STIM1 in store depletion condition. 
Expressed amount of CD20 and STIM1 were compared using WB analysis with 
monoclonal anti-myc antibody for STIM1 and polyclonal anti-flag antibody for CD20. 
(B) The scheme of CD20 protein structure about full length CD20 and C-terminal 
truncated CD20ΔCT (C) Interaction of CD20 with STIM1 in mediated by internal C-
terminal region of CD20. Immunoprecipitation assay show that the internal C-
terminal truncated CD20ΔCT failed to interact with STIM1D76A. (D) CD20 and STIM1 
localization in normal condition (upper) and store depleted condition (5 uM Tg for 
10 min) (bottom) in HEK cells. CD20 and STIM1 were labeled with mouse anti-Flag 
(2nd antibody conjugated with FITC (green)) and anti-STIM1 (2nd antibody 
conjugated with rhodamine (red)), respectively. DAPI (blue) was used for nucleus 
staining. Merged images showed their co localization (yellow) upon store depletion 
condition. White arrows indicate the co-localized CD20 with STIM1. Bar indicated 
5um. 
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Figure 3. Ca2+ influx via CD20 regulated by STIM1 is dependent on Orai1. (A) 
Orai1 dependent STIM1 regulation of Ca2+ influx activity through CD20. siRNA for 
Orai1 was used to determine whether CD20 regulation by STIM1 is dependent on 
Orai1. The relative Ca2+ influx activity was quantified Orai1 dependent protein 
interaction of CD20 and STIM1 in HEK cells using Fura-2 AM fluorescence 
recording. Relative activity was summarized as folds of scramble only treated cells. 
(B) Enhanced protein interaction of CD20 and STIM1 upon increased expression of 
Orai1. Immunoprecipitation assay using monoclonal anti-myc antibody for myc-
STIM1D76A was performed after 0.5 and 1 ug flag-Orai1 with 3xflag-CD20 
overexpression. Each protein expression was confirmed by western blot using anti-
myc and anti-Flag antibodies with lysates and precipitated Flag-Orai1 and 3xflag-
CD20 proteins via by monoclonal anti-myc antibody were detected with polyclonal 
anti-flag antibody. Each protein was indicated as shown in pictures. 
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line known to express CD20. In RT-PCR analysis, endogenous STIM1 and orai1 
mRNA expression of RAMOS cells was observed with CD20 (Fig. 4A). In addition, 
WB analysis for endogenous protein expressions showed that all three proteins were 
expressed in RAMOS cells. STIM1 is observed as monomer and dimer and orai1 
protein also exhibit its monomeric, dimeric and trimeric configurations. (Fig. 4B-C). 
In RAMOS cells, CD20 dominantly exist as a monomer in WB analysis. However, 
CD20 monomers failed to interact, but dimer and tetramer of CD20 interacted with 
STIM1 (Fig. 4D). This interaction was further strengthened by Tg, which corresponds 
to the previous IP experimental data using HEK cells heterologous expression system. 
 
5.  Successful purification of rituximab, obinutuzumab and 
ofatumumab and their quantification 
To produce the antibodies required for the experiment, lentivirus system was 
used the for LC (light chains) and HC (heavy chains) expression. In the case of LC, 
the variable region and the constant region were totally synthesized, while in the case 
of HC, the variable region was synthesized and connected with the constant region 
delivered from the IgG sequences of health volunteer donating blood (Fig. 5A). To 
make obinutuzumab, a glycosylation-engineered antibody on the Fc region, two kinds 
of necessary enzymes were cloned (Fig. 5B) then confirmed their mRNA (Fig. 5C) 
and protein expression of rGNT3 (Fig. 5D) in CHO-K1 cells (Fig. 5B). The antibody 
presence and amount were checked during each step of purification and the size of 
LC (~20 kDa) and HC (~55 kDa) were also confirmed at the reducing condition of 
SDS-PAGE (Fig 5E). To quantify the amount of antibodies, all three antibodies were 
separated in SDS-PAGE of non-reducing condition and visualized with coomassie 
blue staining (Fig. 5F). Indicated amount of BSA were used for the standards for 
protein quantity. These all data demonstrated that the successful establishment for the 
production of rituximab and ofatumumab antibody including the glycol-engineered 
obinutuzumab.   
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Figure 4. Expression of CD20, STIM1 and Orai1 and their interaction in 
RAMOS cell. (A) mRNA expression of CD20, Orai1 and STIM1 was observed via 
RT-PCR analysis with RAMOS cells. Total mRNA was purified from RAMOS cells 
and HEK cells then cDNA was synthesized. Each clone for over-expression was used 
for positive control. PCR products 290bp, 484bp, and 358bp were indicated the 
expression of CD20, STIM1, and Orai1 in RAMOS cells. Protein expressions of 
CD20 (B), STIM1 (C) and Orai1 (D) were checked in RAMOS cell lysate in normal 
and store depletion condition with 5 uM Tg. Goat anti-CD20 antibody, mouse anti-
STIM1 antibody, and rabbit anti-Orai1 antibody were used. Each configuration of 
proteins was indicated as shown. Clone over-expressed lysate was used for positive 
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control for WB. (E) Endogenous protein interaction of CD20 and STIM1 was 
observed in immunoprecipitation assay using RAMOS cell lysate. Resting and store 
depleted condition lysate was immunoprecipitated with monoclonal anti-STIM1 
antibody and precipitated CD20 were identified with goat anti-CD20 antibody. 
Mouse IgG were used for experiment control for IP analysis. In inputs, each over-
expressed CD20 and STIM1 was used for the positive control for WB. Each protein 
was indicated as shown in picture. 
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Figure 5. Successful purification of rituximab, obinutuzumab and ofatumumab 
and their quantification. (A) Schemes for light and heavy chain of monoclonal 
antibody expression in lentivirus production. Poly-nucleotide synthetized regions 
were indicated by gray region and RT-PCR delivered region from IgG were indicated 
by white region. (B) Schemes for glycosylation engineering enzyme used for 
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establishing the glycol-engineered CHO-K1 cells. Human Mannosidase 2 and rat 
GnT-3 enzyme fused with signal sequence from human Mannosidase 2 (100 amino 
acids) were used. rGNT3 with mannosidase signal sequence were tagged with myc 
for protein expression detection. (C) Expression of rGNT3-myc in glycol-engineered 
CHO-K1 cells was identified with anti-myc antibody. (D) mRNA expression of 
human Man2 and rGNT3 with hMan2 signal sequence was confirmed by RT-PCR 
analysis. 330 bp hMan2 and 318 bp rGNT3 were indicated that the glycol-engineered 
CHO-K1 cells and obinutuzumab producing glycol-engineered CHO-K1 cells 
successively expressed both enzymes. 18s rRNA were used for comparison of mRNA 
used. (E) The purification procedure of rituximab, obinutuzumab, and ofatumumab 
were shown by the presence of each monoclonal antibodies in purification steps. 
Lane1, 50 ug of rituximab; lane 2, pre-binding of media; lane 3, post binding of media; 
lane 4, first washing; lane 5, 2nd washing; lane 6, 3rd washing; lane7, 1st elution; 
lane 8, 2nd elution; lane 9, 3rd elution; lane 10, 4th elution; lane 11, 5th elution; lane 
12, 1% triton X-100. (F) Quantification of monoclonal antibodies using BSA protein 
standards. 0.2, 0.4, 0.8, 1.6 and 3.2 ug of BSA and 2 ul of final dialysis monoclonal 
antibodies were SDA-PAGEed in non-reducing condition then coomassie staining 
was performed to visualize proteins. Completed configuration of antibodies was 
identified in 280 kDa. Intensity of protein band were quantified by Multiguige 
software. 
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6.  Validation of accuracy of three antibodies through the binding 
specificity test, acknowledged B cells changes upon their binding, 
and the efficacy of three antibodies on B cell depletion. 
I firstly confirmed their binding specificities by immunostaining assay using 
mCherry-CD20 expressed HEK cells. Immunostaining with each antibody revealed 
that only mCherry-CD20 expressed on the cell membrane was recognized by three 
antibodies (Fig. 6A). To confirm that the effects of antibodies binding were matched 
with previously reports, the capping of CD20, a typical characteristic of type 1 
antibody, and the homotypic adhesion of cells, a typical characteristics of type 2 
antibody were observed after the treatment of three antibodies in RAMOS cells. As 
same as previous reports, rituximab and ofatumumab, but not obinutuzumab caused 
the capping of CD20. In case of the homotypic cell adhesion, obinutuzumab, but not 
rituximab and ofatumumab caused the aggregation of RAMOS cells as similar to 
previous reports. Next, to test their immune function as mAbs, antibody mediated 
direct cell death(DCD), complement dependent cell death (CDC), and effector cell 
mediated cell death (ADCC) were conducted with RAMOS cell (Fig. 6D-F). As 
already reported, type 1 antibody obinutuzumab only showed DCD and this effect 
show dose-dependent manner. On the other hand, under CDC condition, rituximab 
and ofatumumab showed up to 100% cell lysis ability for 2 hr incubation whereas 
obinutuzumab, only showed the half of activity. In ADCC analysis, the cell lysis was 
almost not occurred by rituximab and ofatumumab, but obinutuzumab showed 
significant (20%) cell death treated with 10 ug/ml antibody with effector cell 
(RAMOS : PBMC = 1 : 5). These data demonstrated that rituximab, obinutuzumab, 
and ofatumumab was successively produced having the acknowledged function of 
mAb. 
 
7.  Binding of three antibodies trigger Ca2+ influx from the extracellular 
space 
Prior to investigating the effect of channel property of CD20 on antibody  
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Figure 6. STIM1 controls Orai1 localization in the cell periphery. (A) Binding 
accuracies of rituximab, obinutuzumab, and ofatumumab were confirmed by immune 
staining with mCherry-CD20 expressed HEK cell. Among cells, only mCherry-CD20 
expressed cells showed each antibody bindings via FITC conjugated anti-human Ig 
Fc specific secondary antibody. Nucleus was stained with DAPI. DIC images wand 
DAPI staining showed how many cells were presented in each images. Bar indicates 
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5um. (B) RAMOS cell treated with each antibody were fixed then the localization of 
each antibody according to CD20 movement were observed to confirmed that the 
produced antibodies cause the representative phenomenon in RAMOS cells. To 
visualize caveolin, anti-caveolin1 antibody was used with Alexa350-conjugated 2nd 
antibody. To confirmed the CD20 localization in each monoclonal antibody 
localization, goat-anti-CD20 antibody was used with rhodamine conjugated anti-goat 
2nd antibody. Bar indicates 5uM. DIC images shows the overall morphology of 
RAMOS cells. (C) Homotypic cell adhesion induced by rituximab, obinutuzumab, 
and ofatumumab were observed after 15 minutes of antibody treatment in 37℃. Only 
obinutuzumab showed the aggregation of cells as previously known. Bar indicates 25 
um. Direct antibody binding mediated cell death (D), complement mediated cell death 
(E) and effector cell mediated cell death (F) were tested to confirmed with dose 
dependent increase efficacies of antibodies (0.1, 0.3, 1, 3.2 and 10 ug/ml). Human 
IgG was used for control. 
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function, whether Ca2+ enters the cell when the antibody binds to CD20 must be 
observed. To demonstrate this, alteration of intracellular Ca2+ concentrations treated 
by three antibodies were measured according to time under different external Ca2+ 
conditions. When external Ca2+ was 2 mM, intracellular Ca2+ concentration increased 
with antibody binding to CD20 in both rituximab and obinutuzumab (Fig. 7A). This 
is an antibody-specific response compared to no fluorescence change in the control 
antibody. On the other hand, when external Ca2+ was adjusted to 0 mM, no increase 
in fluorescence was observed (Fig. 7B). This data suggested that the binding of 
rituximab and obinutuzumab cause the Ca2+ influx from outside of cells through 
CD20. 
 
8.  Channel activity of CD20 is enhanced by localization to the non-raft 
region as a result of forming channel complex with STIM1 
To test whether the Ca2+ influx induced by rituximab or obinutuzumab is changed 
by STIM1 expression, the Ca2+ influx was measured with GCamp-CD20 fluorescence 
changes in mock or STIM1 over-expressed HEK cells with FACS analysis. While 
rituximab didn’t make any variation, obinutuzumab treatment induced relative Ca2+ 
influx activity to almost double in STIM1 co-expressed cells than only GCamp-CD20 
expressed cells (Fig. 8A). And the amount of obinutuzumab binding was also 
decreased in STIM1 siRNA treated cells. (Fig. 8C). 
Previous studies have shown that rituximab induce moving of CD20 to lipid raft. 
Because this lipid raft area is resistant to triton, the antibody bound to raft localized 
CD20 remains in cells after washing with 0.5% triton. On the other hand, the 
antibodies are washed away after obinutuzumab binding, which indicated that the 
obinutuzumab bound CD20 is localized in non-raft region in cells (Fig. 8D). STIM1 
siRNA treated RAMOS cells showed that the triton resistant portion of obinutuzumab 
bound CD20 was increased and the washable portion of obinutuzumab bound CD20 
was decreased (Fig. 8E).  
Accordingly, I suggest that CD20 interact with STIM1 has high affinity to bind 
obinutuzumab and seems to localize in the non-raft region, which might contribute  
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Figure 7. Binding of three antibodies trigger Ca2+ influx from the extracellular 
space (A) Treatment of 10 ug/ml anti-goat CD20 (C-term) as control, rituximab, 
obinutuzumab in HEK cells expressing CD20 cause the Ca2+ influx from the external 
space. HEK cell expressing CD20 were stained with Fluo-4-AM then Ca2+ changes 
upon rituximab were monitored confocal microscopy for the time dependent changes 
30 
 
of intracellular Ca2+ changes. Arrow indicate the changed Fluo-4 fluorescence upon 
rituximab treatment. Bar indicates 5um and yellow number indicate the time at 
pictured. (B) Same experiment but used Ca2+ free external solution was performed 
the changes the intracellular Ca2+ caused by Ca2+ influx from the outside of cells. 
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Figure 8. Channel activity of CD20 is enhanced by localization to the non-raft 
region as a result of forming channel complex with STIM1. (A) rituximab and 
obinutuzumab induced Ca2+ influx activity was measured by fluorescence changes of 
GCamp 6.S-CD20. To test the effect of STIM1 binding to CD20, mock or STIM1 
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was co-expressed with GCamp6.S-CD20 in HEK cell. The fluorescence changes after 
antibody treatment with 2 mM Ca2+ were measured with FACS, then the increased 
fluorescence was summarized as a fold of CD20 only expressed HEK cells treated 
with rituximab. ***p<0.001. (B) Protein expression of STIM1 significantly reduced 
by siRNA in RAMOS cells. (C) To test binding property of CD20 upon STIM1 
knockdown, RAMOS cells transfected with scramble or siSTIM1 were treated with 
rituximab or obinutuzumab, then their binding amount were quantified by the FITC 
conjugated secondary antibodies. In siSTIM1 treated condition, the antibody CD20 
were decreased. (D) Cartoon for the quantification of raft localized CD20 using triton 
X-100 solubility test. Raft localized CD20 and non-raft localized CD20 were 
indicated with blue and gray color, respectively. Treatment of 0.5% triton X-100 
treatment solubilized the non-raft localized CD20 (gray), then raft localized CD20 
were left. Since rituximab binds to the raft localized CD20 and obinutuzumab binds 
to non-raft localized CD20. 0.5% triton treatment caused no fluorescence changes in 
FITC-rituximab bound CD20, but it caused large decreased fluorescence FITC-
obinutuzumab bound CD20. (E) To test the raft localization property of CD20 upon 
STIM1 binding, RAMOS cells transfected with scramble or siSTIM1 were treated 
with rituximab or obinutuzumab, then their binding amount were quantified by the 
FITC conjugated secondary antibodies. In siSTIM1 treated condition, the 
insolubilized CD20 were increased. 
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the efficacy of direct binding mediated cell death via obinutuzumab. 
 
9.  External Ca2+ is essential for the homotypic adhesion, but not 
required for direct binding mediated cell death by obinutuzumab. It 
is dependent on the external concentration of Mg2+ 
 
In some of previous studies, HA (homotypic adhesion) induced by 
obinutuzumab is the main cause of obinutuzumab induced DCD (direct cell death). 
To observe the Ca2+ dependency of the HA and DCD by obinutuzumab, HA and DCD 
was tested the in 2mM Ca2+ or Ca2+ free external solutions. As expected, 
obinutuzumab induced HA was only occurred in 2mM Ca2+ external solution, which 
implied that homotypic adhesion by obinutuzumab is dependent on extracellular Ca2+. 
(Fig. 9A). But unexpectedly, DCD was not affected by extracellular Ca2+ 
concentration, even more DCD seems to be happened in Ca2+ free external solution 
than 2mM Ca2+ condition (Fig. 9B). Since DCD was not affected by Ca2+, I searched 
which ion is related with DCD by obinutuzumab. Among various ion, Mg2+ 
concentration exhibit potential effect on DCD, and then Mg2+ concentration was 
variated in external solution. In normal Mg2+ range, 1.5 mM Mg2+, obinutuzumab had 
a superior effect on DCD. But the degree of DCD is not different between rituximab 
and obinutuzumab in 0 mM Mg2+. In addition, when the magnesium concentration is 
increased up to 5mM and 10mM, the rate of DCD is also similar between rituximab 
and obinutuzumab. These data indicated that the typical DCD induced by 
obinutuzumab is totally dependent on the Mg2+ concentration in external solution, 
which might imply that the Mg2+ permeability through CD20 is the main cause of the 
DCD via obinutuzumab binding in RAMOS cells (Fig. 9C). 
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Figure 9. External Ca2+ is essential for the homotypic adhesion, but not required 
for direct binding mediated cell death by obinutuzumab. (A) To determine the 
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Ca2+ dependency of the obinutuzumab induced phenomenon, homotypic adhesion 
was observed in 2 mM Ca2+ and Ca2+ free solution. rituximab and ofatumumab did 
not showed any homotypic cell aggregation in both solution, but obinutuzumab 
showed cell aggregation only in 2 mM Ca2+ solution. (B) Direct binding mediated 
cell death were tested is a various concentration of rituximab, obinutuzumab, and 
ofatumumab in 2 mM Ca2+ or Ca2+ free external solution. In both solution, rituximab 
and ofatumumab did not showed any cell death via binding, but only obinutuzumab 
showed direct cell death in both solutions. (C) Mg2+ dependent direct cell death 
mediated by obinutuzumab binding. To test whether Mg2+ concentration in external 
solution is related with obinutuzumab induced direct binding mediated cell death in 
RAMOS cells, Mg2+ free, 1.5mM Mg2+, 5 mM Mg2+, 10 mM Mg2+ and bafilomycin 
treated in 1.5 mM Mg2+ were used then antibodies were treated for 12 hr. The cell 
lysis % were depicted as a graph. *p<0.05 and ns, not significant. 4 independent 
experiment summarized in graph. 
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IV. DISCUSSION 
 
In spite of previous intensive study, as yet no clear function or ligand has been 
revealed for CD20, and only clinical effects were studied well. Store operated calcium 
influx was observed in cells transfected with CD20 at 2003, but there is still 
controversy as to whether CD20 itself has a channel function. 
In this study, the pore function of CD20 as a SOC channel was studied by 
examining the molecular interactions with stim1 and identified how the pore function 
of CD20 effects on the function of anti-CD20 antibodies, rituximab and 
obinutuzumab. 
To understand the pore function of CD20, the interaction of CD20 with STIM1 
was observed in heterologous expression system and RAMOS cells. And I found their 
enhanced interaction in store depletion, and constitutive activation form of STIM1 
which proves that the CD20 is a store operated channel. In addition, the CD20 channel 
activity regulated by STIM1 is dependent on Orai1, which implied that CD20 
involved in the protein complexes with orai1 and STIM1 to function as SOC channel.  
Next, it should be noted that the Ca2+ influx induced by antibody binding. In 
previous study, rituximab was crosslinked with a second polyclonal antibody to 
generate a calcium flux in Ramos cell. But in our image based data, external Ca2+ 
influx was observed even without crosslinking in Ramos cell. Considering the same 
phenomenon appears in cells expressing high level of cd20 such as Daudi or SU-
DHL-423, this is thought to be caused by the difference in the expression level of 
CD20 and CD20 expression may change depending on the culture environment.  
Meanwhile, the Ca2+ influx induced by binding of obinutuzumab on CD20 was 
enhanced by STIM1 co-expression. Moreover, the binding affinity to obinutuzumab 
was attenuated by knock-down of STIM1 expression using siRNA for STIM1. 
Besides, non-raft localized CD20 were decreased by siSTIM1 treated RAMOS cells. 
These results support that the configuration of CD20 is largely divided into two forms 
(lipid raft form and non-lipid raft form) and each function will be different. In addition, 
obinutuzumab causes the change of CD20 configuration to migrate into the non-lipid 
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raft region, which might activate the pore function of CD20 and induce the typical 
cell death. Thus, these all data demonstrated that the CD20 configuration regulated 
by STIM1 is effects on the function of anti-CD20 antibodies, especially 
obinutuzumab.  
Next, focusing on the physiological function of the antibody, the homotypic 
adhesion and direct cell death induced by obinutuzumab. HA and DCD, which is a 
typical phenomenon that occur only by obinutuzumab, were expected to be Ca2+ 
dependent phenomenon and HA is known to as a main cause of DCD in previous 
report.9,18 However, HA is occurred in a Ca2+ dependent manner, but external Ca2+ 
did not effect on the DCD. So HA is considered to be a secondary event occurring 
after DCD. Further study using latrunculin or actinomycine, the actin immobilizing 
drug, will be revealed that the DCD process has priority over HA. 
In our study, even if the direct cell death induced by obinutuzumab is not 
dependent on the external Ca2+ concentration, I cannot not exclude that the pore 
function of CD20 is required for DCD by the obinutuzumab, because the Mg2+ 
concentration in external solution is critical for the DCD. At present, I don’t know 
why the Mg2+ in external solution is required for the DCD by obinutuzumab. Further 
study showing the Mg2+ influx changes by obinutuzumab will clarify the Mg2+ pore 
function of CD20 and its relation of DCD by obinutuzumab. In a previous study, there 
was a report that DCD might be associated with the explosion of lysosomes. 9,19,20 
The lysosome has a pH control mechanism regulated Mg2+, therefore I expect that the 
Mg2+ may be involved in DCD process.21,22 
In conclusion, the possibility that CD20 enact as a pore and that could 
influence function of antibody. Even if external Ca2+ didn’t affect the DCD by 
obinutuzumab, there are the possibility that influx of other ions such as Mg2+ 
through CD20 could regulate the DCD by obinutuzumab. 
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V. CONCLUSION 
In this study, I demonstrate that CD20 enact as a pore and CD20 involved in a 
protein complexes with Orai1 and STIM1 to function as SOC channel. This 
configuration of CD20 being regulated by STIM1 contributes to the efficacy of anti-
CD20 antibodies. Especially, obinutuzumab causes the change of CD20 
configuration to migrate into the non-lipid raft region and activate the pore function 
of CD20. Perhaps, the permeability of Mg2+ through CD20 might be involved in DCD 
by obinutuzumab.  
 
 
 
  
39 
 
REFERENCES 
1. Tedder TF, Klejman G, Disteche CM, Adler DA, Schlossman SF, Saito 
H. Cloning of a complementary DNA encoding a new mouse B 
lymphocyte differentiation antigen, homologous to the human B1 
(CD20) antigen, and localization of the gene to chromosome 19. J 
Immunol 1988;141:4388-94. 
2. Walport M, Murphy K, Janeway C, Travers PJ. Janeway's 
Immunobiology (7th ed). 2008. 
3. Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region 
of CD20 required for its redistribution to a detergent-insoluble 
membrane compartment. J Immunol 1998;161:3242-8. 
4. Janas E, Priest R, Wilde JI, White JH, Malhotra R. rituximab (anti-
CD20 antibody)-induced translocation of CD20 into lipid rafts is 
crucial for calcium influx and apoptosis. Clin Exp Immunol 
2005;139:439-46. 
5. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et 
al. Increasing the efficacy of CD20 antibody therapy through the 
engineering of a new type II anti-CD20 antibody with enhanced direct 
and immune effector cell-mediated B-cell cytotoxicity. Blood 
2010;115:4393-402. 
6. Kern DJ, James BR, Blackwell S, Gassner C, Klein C, Weiner GJ. 
GA101 induces NK-cell activation and antibody-dependent cellular 
cytotoxicity more effectively than rituximab when complement is 
present. Leuk Lymphoma 2013;54:2500-5. 
7. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, et al. 
Antigenic modulation limits the efficacy of anti-CD20 antibodies: 
implications for antibody selection. Blood 2010;115:5191-201. 
8. Klein C, Lammens A, Schafer W, Georges G, Schwaiger M, Mossner 
E, et al. Epitope interactions of monoclonal antibodies targeting CD20 
and their relationship to functional properties. MAbs 2013;5:22-33. 
9. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, 
et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes 
40 
 
homotypic adhesion and actin-dependent, lysosome-mediated cell 
death in B-cell malignancies. Blood 2011;117:4519-29. 
10. Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry 
mediated by CD20 in membrane rafts. J Biol Chem 2003;278:42427-
34. 
11. Vacher P, Vacher AM, Pineau R, Latour S, Soubeyran I, Pangault C, et 
al. Localized Store-Operated Calcium Influx Represses CD95-
Dependent Apoptotic Effects of rituximab in Non-Hodgkin B 
Lymphomas. J Immunol 2015;195:2207-15. 
12. Lewis RS. The molecular choreography of a store-operated calcium 
channel. Nature 2007;446:284-7. 
13. Parker NJ, Begley CG, Smith PJ, Fox RM. Molecular cloning of a 
novel human gene (D11S4896E) at chromosomal region 11p15.5. 
Genomics 1996;37:253-6. 
14. Williams RT, Manji SS, Parker NJ, Hancock MS, Van Stekelenburg L, 
Eid JP, et al. Identification and characterization of the STIM (stromal 
interaction molecule) gene family: coding for a novel class of 
transmembrane proteins. Biochem J 2001;357:673-85. 
15. Roos J, DiGregorio PJ, Yeromin AV, Ohlsen K, Lioudyno M, Zhang S, 
et al. STIM1, an essential and conserved component of store-operated 
Ca2+ channel function. J Cell Biol 2005;169:435-45. 
16. Liou J, Kim ML, Heo WD, Jones JT, Myers JW, Ferrell JE, Jr., et al. 
STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ 
influx. Curr Biol 2005;15:1235-41. 
17. Zhou Y, Srinivasan P, Razavi S, Seymour S, Meraner P, Gudlur A, et 
al. Initial activation of STIM1, the regulator of store-operated calcium 
entry. Nat Struct Mol Biol 2013;20:973-81. 
18. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna 
M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 
monoclonal antibody GA101 in B-chronic lymphocytic leukemia 
whole blood assays in comparison with rituximab and alemtuzumab. J 
Immunol 2011;186:3762-9. 
41 
 
19. Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, 
Ivanov A, et al. Antibody-induced nonapoptotic cell death in human 
lymphoma and leukemia cells is mediated through a novel reactive 
oxygen species-dependent pathway. Blood 2012;119:3523-33. 
20. Jak M, van Bochove GG, Reits EA, Kallemeijn WW, Tromp JM, 
Umana P, et al. CD40 stimulation sensitizes CLL cells to lysosomal 
cell death induction by type II anti-CD20 mAb GA101. Blood 
2011;118:5178-88. 
21. Jha A, Ahuja M, Patel S, Brailoiu E, Muallem S. Convergent regulation 
of the lysosomal two-pore channel-2 by Mg2+, NAADP, PI3,5P2 and 
multiple protein kinases. Embo j 2014;33:501-11. 
22. Miao Y, Li G, Zhang X, Xu H, Abraham SN. A TRP Channel Senses 
Lysosome Neutralization by Pathogens to Trigger Their Expulsion. 
Cell 2015;161:1306-19. 
23. Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, Packham 
GK, et al. Induction of cytosolic calcium flux by CD20 is dependent 
upon B Cell antigen receptor signaling. J Biol Chem 2008;283:16971-
84. 
 
  
42 
 
ABSTRACT (in Korean) 
 
CD20의 칼슘통로활성이 Rituximab과 Obinutuzumab의  
효능에 미치는 영향 
 
<지도교수 김 주 영> 
 
연세대학교 대학원 의과학과 
 
허   운 
 
 
CD20은 세포막을 4번 통과하는 단백으로서, 비호치킨성 림프종의 
치료제와 만성관절염의 치료제의 표적이 되는 단백이다. CD20이 SOC통로특성을 
가지고 있음은 기존의 여러 연구에서 보고하였지만, CD20이 SOC 통로라는 결론을 
확실히 내릴 수 있는 STIM1과의 결합 여부에 대한 보고는 전무하다.  
이를 바탕으로 본 논문에서는 1) CD20의 세포막 통로로서의 특성 파악과 
2) SOC 기전을 통한 칼슘 신호가 각 항체에 대한 역가나 특성을 결정하는데 
어떠한 영향을 미칠 것인지 규명하고자 하였다. 
CD20와 STIM1의 단백상호작용 확인한 결과, CD20이 STIM1과 상호작용은 
세포내 칼슘저장고 고갈에 의해서 증가할 뿐 아니라 Orai1에 의존적인 것이 
확인되었다. 이는 CD20이 단독으로 세포막 통로로서 작용한다기보다 STIM1과 
Orai1이 이루는 단백복합체에 참여한다 
항체를 생산함에 있어선 lentivirus system을 이용하였으며 항체의 생산, 
정제 과정, 정제 후 과정에서 정상적인 항체가 만들어졌는지 확인하였다. 그 
결과 항원 특이성, 각 항체의 특이적 기능 등이 알려진 바와 일치하였다. 
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생산된 항체를 각각 CD20가 과 발현 된 HEK293T 세포에 처리한 결과 
rituximab 과 obinutuzumab 모두 외부로부터의 칼슘 유입을 보였으나 STIM1과의 
단백 상호 작용은 항체의 종류에 따라 다른 영향을 미쳤다. rituximab 의 경우, 
CD20와 STIM1의 결합으로 인한 영향이 미미했던 반면에, obinutuzumab 의 경우 
항원인 CD20에 결합하는 능력과 외부로부터 들어오는 칼슘의 양이 모두 
유의하게 증가하였다. 이는 STIM1과 상호작용하는 CD20 세포막 통로적 특징이 
항체의 기능에 선택적으로 영향을 줄 수 있음을 시사한다. 
obinutuzumab 특이적인 세포 동형성 접착 현상(homotypic adhesion)과 
직접적 세포사멸 기전(direct cell death)이 외부 칼슘 농도에 의존적인지 
살펴본 결과 흥미롭게도, 세포 동형성 접착의 경우 외부 칼슘 농도의존적으로 
일어나는 반면 직접적 항체 결합에 의한 세포 사멸의 경우 외부 칼슘 농도에 
상관 없이 일어남을 보였다. obinutuzumab 에 의한 직접적 항체 결합에 의한 
세포 사멸이 칼슘 이외의 이온의 연관성을 살펴본 결과 세포 외부의 마그네슘 
농도가 obinutuzumab 결합의존적 세포사멸에 중요함을 발견하였다.   
결론적으로 본 연구는 CD20이 STIM1과 Orai1의존적으로 기능하는 세포내 
칼슘저장고 의존적 칼슘 통로이며 이러한 CD20의 칼슘통로로서의 특성은 각 
항체 rituximab 과 obinutuzumab 의 결합에 의해서 활성화됨을 규명하였다. 
특히 obinutuzumab 에 의한 항체 결합-의존적 세포사멸은 CD20의 Mg2+통과 
기능과 연관되어 있을 것으로 생각한다.    
 
 
 
 
 
 
 
 
 
핵심되는 말: CD20, STIM1, SOCE, 칼슘, 마그네슘, rituximab, obinutuzumab.  
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